P587: REAL-WORLD CHARACTERISTICS AND USE OF ANTIEMETIC THERAPIES AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ORAL AZACITIDINE MAINTENANCE THERAPY

P587: REAL-WORLD CHARACTERISTICS AND USE OF ANTIEMETIC THERAPIES AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ORAL AZACITIDINE MAINTENANCE THERAPY

Bibliographic Details
Main Authors:	Ying Qiu, Jiafan Chen, Gautam Sajeev, Yao Wang, Dongni Ye, Mingchen Ye, Jingyi Chen, Allison Quintana, Clare Byrne, David Huggar, Willem Heydendael
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969252.00953.ba

Similar Items

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

Role of ganaton in antiemetic therapy. New treatment capacities
by: A. V. Snegovoy, et al.
Published: (2014-08-01)

EXPLORING THE EFFICACY OF AZACITIDINE AND VENETOCLAX COMBINATION IN TREATING ACUTE MYELOID LEUKEMIA IN CASES OF RELAPSE FOLLOWING AZACITIDINE TREATMENT AND HIGH-DOSE VITAMINS THERAPY
by: VM Sthel, et al.
Published: (2023-10-01)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
by: Ryosuke Naka, et al.
Published: (2023-08-01)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
by: Craddock, C, et al.
Published: (2017)

P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
by: Keri Maher, et al.
Published: (2023-08-01)

Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia
by: Fang Zheng, et al.
Published: (2023-12-01)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
by: Linyu Yuan, et al.
Published: (2023-08-01)

Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
by: António Araújo, et al.
Published: (2023-01-01)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature
by: Stuart H. Isaacson, et al.
Published: (2023-01-01)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
by: H. Dohner, et al.
Published: (2022-06-01)

Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2
by: Rachel Culp-Hill, et al.
Published: (2023-03-01)

Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region
by: Takayuki Ide, et al.
Published: (2023-06-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
by: Loke, J, et al.
Published: (2021)

Targeting PRAME for acute myeloid leukemia therapy
by: Jinjun Yang, et al.
Published: (2024-03-01)

P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: A. M. Zeidan, et al.
Published: (2022-06-01)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
by: Shimokawa M, et al.
Published: (2022-09-01)

EAV587 - ENVIRONMENTAL RISKS ASSESSMENT. MARCH 2003
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2003)

Scribes Before and After 587 BCE: A Conversation
by: Mark Leuchter, et al.
Published: (2009-03-01)

Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia with NUP98-RARG Gene Fusion
by: Jiaojiao Yuan, et al.
Published: (2023-03-01)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
by: A. Schuh, et al.
Published: (2022-06-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
by: S. de Botton, et al.
Published: (2022-06-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Therapeutic study of the nausea and vomiting caused by chemotherapy medications by olanzapine to triple antiemetic therapy in Iraqi cancer patients
by: Ghufran salah ahmed, et al.
Published: (2023-05-01)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
by: Unnikrishnan, A, et al.
Published: (2017)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial
by: Xiao Li, et al.
Published: (2024-04-01)

ENU-induced phenovariance in mice: inferences from 587 mutations.
by: Arnold, C, et al.
Published: (2012)

L30S F587 (87-100) [fotograf udara]

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
by: Ai Asai-Nishishita, et al.
Published: (2023-09-01)

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
by: Friedrich Stölzel, et al.
Published: (2023-01-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment
by: Hongxia Chen, et al.
Published: (2024-03-01)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
by: Hong Pan, et al.
Published: (2023-08-01)

Immune therapy: a new therapy for acute myeloid leukemia
by: Chen Tian, et al.
Published: (2023-03-01)

High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia
by: Sing-Ting Wang, et al.
Published: (2022-11-01)

EAV 587-4 ENVIRONMENTAL RISKS ASSESSMENT FEB-MAR 03.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2003)